| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Lloyd George W. | EVP, Investments & CLO | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK | /s/ Sean Weisberg, as Attorney-in-Fact for George W. Lloyd | 19 Dec 2025 | 0001814899 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RPRX | Class A Ordinary Shares | Sale | -$3.06M | -79.3K | -72.13% | $38.57 | 30.7K | 17 Dec 2025 | By GWL 2014 G, LLC | F1, F2 |
| transaction | RPRX | Class A Ordinary Shares | Sale | -$1.18M | -30.7K | -100% | $38.50 | 0 | 18 Dec 2025 | By GWL 2014 G, LLC | F1, F3 |
| holding | RPRX | Class A Ordinary Shares | 496K | 17 Dec 2025 | By GWL 2013 NG, LLC | ||||||
| holding | RPRX | Class A Ordinary Shares | 274K | 17 Dec 2025 | By IRA | ||||||
| holding | RPRX | Class A Ordinary Shares | 6.08K | 17 Dec 2025 | By GWL 2023 G HoldCo LLC | ||||||
| holding | RPRX | Class A Ordinary Shares | 4.01K | 17 Dec 2025 | By Spouse |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. |
| F2 | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 7,527,320 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,944,471 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.